Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD

  • Lea Price
  • Sarah J. Billups
  • Melissa A. Rice
  • Cynthia Hartsfield
Keywords: Pulmonary Disease, Chronic Obstructive, Practice Guidelines, Drug Therapy, Patient Compliance, United States

Abstract

Background: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care.

Objective: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors.

Methods: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history.

Results: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions.

Conclusions: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment.

Downloads

Download data is not yet available.

References

1. National Heart, Lung, and Blood Institute/World Health Organization. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report- Executive Summary. 2005. Available at: www.goldcopd.com. (Accessed December 12 2006).

2. National Institutes of Health: National Heart, Lung, and Blood Institute. Chronic obstructive pulmonary disease. NIH Publication 03-5229, 2003 March. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf. (Accessed August 15, 2006).

3. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77-S121.

4. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-1420.

5. National Heart, Lung, and Blood Institute/World Health Organization. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report- Executive Summary. 2001. Available from: www.goldcopd.com. (Accessed December 12, 2006)

6. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.

7. Ulrik C. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomized, double blind, placebo controlled, crossover study. Thorax. 1995;50:750-4.

8. Matheson MC, Abeysena C, Raven JM, Skoric B, Johns DP, Abramson MJ, Walters EH. How have we been managing chronic obstructive pulmonary disease in Australia? Int Med J 2006;36(2):92-9.

9. Lindenauer PK, Pekow P, Gao S, Crawford AS, Guierrez B, Bejamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903.

10. Harvey PA, Murphy MC, Dornom E, Berlowitz DJ, Lim WK, Jackson B. Implementing evidence-based guidelines: inpatient management of chronic obstructive pulmonary disease. Intern Med J 2005;35:151-5.

11. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 2003;8:504-8.

12. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Lung Health Study. Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 1995;152:580-8.

13. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest 2005;128:3198-3204.

14. Brand C, Landgren F, Hutchinson A, Jones C, MacGregor L, Campbell D. Clinical practice guidelines: barriers to durability after effective early implementation. Intern Med J. 2005;35:162-9.

15. Hartsfield CL, Shetterly S, Palen TE, McCoy M, Marton JP. COPD: Treatment and utilization patterns in managed care. Am J Respir Crit Care Med 2005 [Abstract #A541].

16. Sandhoff BG, Nies LK, Olson KL, Nash JD, Rasmussen JR, Merenich JA. Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in health maintenance organization. Am J Health Syst Pharm 2007;64:77-84.

17. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-22.
Published
2007-06-18
How to Cite
1.
Price L, Billups SJ, Rice MA, Hartsfield C. Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD. Pharm Pract (Granada) [Internet]. 2007Jun.18 [cited 2019Aug.21];5(2):74-7. Available from: https://pharmacypractice.org/journal/index.php/pp/article/view/256
Section
Original Research